Yoshiteru Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yoshiteru Sasaki has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Baochun Zhang
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
1 shared publication - Dinis Pedro Calado
Immunity and Cancer Laboratory, Francis Crick Institute, London, UK
1 shared publication - Emmanuel Derudder
Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, Austria
1 shared publication - Fabienne Mackay
Department of Microbiology and Immunology University of Melbourne at The Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia
1 shared publication - Klaus Rajewsky
Program in Cellular and Molecular Medicine, Children’s Hospital, and Immune Disease Institute, Harvard Medical School, Boston, USA
1 shared publication - Marc Schmidt-Supprian
Max Planck Institute of Biochemistry Martinsried Germany
1 shared publication
Latest Publications
- Open Access
- 5 August 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (31) , 10883-10888
NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells
BAFF-R-dependent activation of the alternative NF-κB pathway plays an essential role in mature B cell survival. Mutations leading to overexpression of NIK and deletion of the TRAF3 gene are implicated in human multiple myeloma. We show that overexpression of NIK in mouse B lymphocytes amplifies alternative NF-κB activation and peripheral B cell numbers in a BAFF-R-dependent manner, whereas uncoupling NIK from TRAF3-mediated control causes maximal p100 processing and dramatic hyperplasia of BAFF-R-independent B cells. NIK controls alternative NF-κB signaling by increasing the protein levels of its negative regulator TRAF3 in a dose-dependent fashion. This mechanism keeps NIK protein levels below detection even when they cause B cell hyperplasia, so that contributions of NIK to B cell pathologies can easily be overlooked.
- 5 August 2008
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 105 (31) , 10883-10888
Open AccessNIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells
BAFF-R-dependent activation of the alternative NF-κB pathway plays an essential role in mature B cell survival. Mutations leading to overexpression of NIK and deletion of the TRAF3 gene are implicated in human multiple myeloma. We show that overexpression of NIK in mouse B lymphocytes amplifies alternative NF-κB activation and peripheral B cell numbers in a BAFF-R-dependent manner, whereas uncoupling NIK from TRAF3-mediated control causes maximal p100 processing and dramatic hyperplasia of BAFF-R-independent B cells. NIK controls alternative NF-κB signaling by increasing the protein levels of its negative regulator TRAF3 in a dose-dependent fashion. This mechanism keeps NIK protein levels below detection even when they cause B cell hyperplasia, so that contributions of NIK to B cell pathologies can easily be overlooked.